Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer

Table 1 Cox univariate and multivariable analysis of pSTAT3-GS treated as a continuous variable, in the FinHer study

	DDFS prognostic value of pSTAT3-GS (No trastuzumab)						DDFS prognostic value of pSTAT3-GS (trastuzumab)
	Univariate			Multivariate			Univariate			Multivariate			P interaction
	HR	95 % CI	P	HR	95 % CI	P	HR	95 % CI	P	HR	95 % CI	P
All	0.77	0.53–1.13	0.18	0.77	0.52–1.13	0.19	0.95	0.58–1.55	0.84	0.99	0.6–1.67	0.99	0.41
ER–	0.67	0.39–1.15	0.14	0.66	0.39–1.12	0.12	2.24	1.2–4.16	0.01	1.73	0.87–3.45	0.12	0.02
ER+	0.81	0.46–1.41	0.45	0.73	0.35–1.53	0.41	0.34	0.14–0.77	0.01	0.36	0.14–0.98	0.04	0.24

DDFS, Distant disease free survival; HR, Hazards ratio; CI, Confidence interval; ER, Estrogen receptor
For multivariate analysis, we considered the following variables: age, tumor size, grade, nodal status, and ER status (when ER was used to stratify the groups it was not used in the multivariate model). Interaction test for the multivariate analysis

ISSN: 1741-7015